PI3K mutant breast cancer treatment options have rapidly evolved over the past decade, reflecting a deeper understanding of oncogenic signaling pathways and the limitations of earlier targeted therapies. Among hormone receptor-positive (HR+), HER2-negative metastatic breast cancer, activating mutations in the PIK3CA gene are present in approximately 35–40% of patients, making the PI3K pathway one of the most clinically relevant therapeutic targets in this disease (Andre et al., 2019).
The PI3K/AKT/mTOR pathway plays a central role in tumor growth, survival, metabolic regulation, and endocrine resistance. Dysregulation of this pathway contributes not only to tumor progression but also to resistance to standard endocrine therapies, particularly in patients previously exposed to CDK4/6 inhibitors. As a result, targeting PI3Kα has emerged as a cornerstone strategy in managing advanced HR+ breast cancer.
Despite early enthusiasm, the clinical development of PI3K inhibitors has been challenged by toxicity, limited selectivity, and modest durability of response. However, newer agents, including mutant-selective and allosteric inhibitors, are redefining PI3K mutant breast cancer treatment options and offering renewed hope for improved outcomes.
The Biological Rationale for Targeting PI3K
The PI3K pathway is activated by growth factor receptors and downstream signaling cascades that regulate cell proliferation and survival. In breast cancer, PIK3CA mutations lead to constitutive activation of PI3Kα, promoting oncogenesis and therapeutic resistance.
Importantly, PI3K pathway activation is strongly associated with resistance to endocrine therapy, which remains the backbone of treatment for HR+ disease. This has led to the development of combination strategies integrating PI3K inhibitors with endocrine agents such as fulvestrant or aromatase inhibitors.
However, early PI3K inhibitors lacked specificity, targeting multiple isoforms and leading to significant toxicity, including hyperglycemia, rash, and gastrointestinal side effects. This has driven the development of more selective agents aimed at improving the therapeutic index.
Alpelisib: The First Approved PI3Kα Inhibitor
Alpelisib represents the first clinically approved PI3Kα-specific inhibitor and marked a major milestone in PI3K mutant breast cancer treatment options.
SOLAR-1 Trial
The pivotal SOLAR-1 trial evaluated alpelisib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer harboring PIK3CA mutations. The study demonstrated a significant improvement in progression-free survival (PFS), with a median PFS of 11.0 months in the alpelisib arm versus 5.7 months in the placebo arm (Andre et al., 2019).
These results established alpelisib as a standard treatment option in patients with PIK3CA-mutated disease following progression on endocrine therapy.
BYLieve Study
The BYLieve trial further evaluated alpelisib in patients previously treated with CDK4/6 inhibitors, reflecting a more contemporary treatment landscape. In this setting, median PFS was approximately 7.3 months, confirming activity in a heavily pretreated population (Rugo et al., 2021).
Limitations
Despite its efficacy, alpelisib is associated with significant toxicity, particularly hyperglycemia, which occurs in a substantial proportion of patients. This toxicity profile often necessitates dose modifications and limits its broader applicability.
Thus, while alpelisib remains a cornerstone, its limitations have highlighted the need for next-generation PI3K inhibitors.
Inavolisib: Next-Generation Selective PI3Kα Inhibition
Inavolisib is a highly selective PI3Kα inhibitor designed to improve efficacy while reducing off-target toxicity. It also promotes degradation of mutant PI3Kα, offering a novel mechanism of action.
INAVO120 Trial
The INAVO120 Phase III trial evaluated inavolisib in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated HR+/HER2- metastatic breast cancer. The trial demonstrated a marked improvement in progression-free survival, with a median PFS of 15.0 months versus 7.3 months in the control arm (Juric et al., 2023).
This represents one of the most significant advances in PI3K mutant breast cancer treatment options in recent years, particularly in the first-line metastatic setting.
Read About INAVO120 Trial on OncoDaily
Safety Profile
Inavolisib has shown a more favorable safety profile compared to earlier PI3K inhibitors, with reduced incidence of high-grade hyperglycemia and improved tolerability, allowing for better treatment adherence.
Capivasertib and the Broader PI3K Pathway
While not a direct PI3K inhibitor, capivasertib targets AKT, a key downstream effector of the PI3K pathway. The CAPItello-291 trial demonstrated that capivasertib plus fulvestrant significantly improved PFS in patients with pathway alterations, including PIK3CA mutations, with a median PFS of 7.2 months versus 3.6 months in the control arm (Turner et al., 2023).
This highlights the importance of targeting the broader pathway, expanding PI3K mutant breast cancer treatment options beyond direct PI3K inhibition.
Gedatolisib: Dual PI3K/mTOR Inhibition
Gedatolisib represents a distinct approach within PI3K mutant breast cancer treatment options by targeting both PI3K and mTOR signaling pathways simultaneously. Unlike isoform-selective inhibitors such as alpelisib, gedatolisib inhibits all class I PI3K isoforms along with mTOR, aiming to overcome compensatory feedback activation and improve pathway suppression.
VIKTORIA-1 Trial
The VIKTORIA-1 Phase III trial is evaluating gedatolisib in combination with fulvestrant, with or without CDK4/6 inhibition, in patients with HR+/HER2- advanced breast cancer who have progressed on prior endocrine therapy.
Early data suggest a significant improvement in progression-free survival compared to fulvestrant alone, particularly in patients with PI3K pathway alterations (Jhaveri et al., 2024), supporting the role of broader pathway inhibition in endocrine-resistant disease.
Earlier Phase Studies
In Phase Ib/II trials, gedatolisib combined with endocrine therapy demonstrated:
- Objective response rate (ORR): 25–40%
- Median progression-free survival (PFS): 7–10 months
These results indicate meaningful activity in pretreated populations with PI3K pathway dysregulation (Jhaveri et al., 2021).
Safety Profile
Gedatolisib is associated with a broader toxicity profile compared to selective PI3Kα inhibitors, reflecting its mechanism of action:
- Hyperglycemia
- Mucositis
- Gastrointestinal toxicity
While generally manageable, these adverse events highlight the balance between broader pathway inhibition and tolerability.
Read About VICTORIA-1 Trial on OncoDaily
Zovegalisib: A New Generation of PI3Kα Inhibition
Zovegalisib (RLY-2608) represents a novel class of allosteric, mutant-selective PI3Kα inhibitors, designed to overcome the limitations of earlier agents.
Mechanistic Innovation
Unlike traditional orthosteric inhibitors, zovegalisib targets an allosteric site, allowing for greater selectivity between mutant and wild-type PI3Kα. This approach reduces off-target toxicity while maintaining potent inhibition of oncogenic signaling.
Preclinical studies demonstrated that zovegalisib achieves sustained pathway inhibition with improved tolerability, supporting its clinical development.
ReDiscover Trial: Phase 1/2 Data
The ongoing ReDiscover Phase 1/2 trial evaluated zovegalisib in combination with fulvestrant in patients with PIK3CA-mutated HR+/HER2- metastatic breast cancer previously treated with CDK4/6 inhibitors.
Efficacy Results
At the recommended Phase 3 dose of 400 mg BID (fed):
- Median PFS reached 11.1 months
- Comparable efficacy across mutation types:
- 11.2 months (kinase domain)
- 11.0 months (non-kinase domain)
- Objective response rate (ORR):
- 43% overall
- 52% in second-line patients
These results are particularly notable given the heavily pretreated population.
Safety and Tolerability
Zovegalisib demonstrated a favorable safety profile:
- Predominantly low-grade adverse events
- Minimal severe hyperglycemia
- Low discontinuation rates (only 4 patients)
Importantly, hyperglycemia events were mostly Grade 1, with no Grade 4–5 events reported. This represents a significant improvement compared to earlier PI3K inhibitors.
ReDiscover-2: Phase 3 Trial
The ReDiscover-2 Phase 3 trial is currently evaluating zovegalisib plus fulvestrant versus capivasertib plus fulvestrant in patients with PIK3CA-mutated HR+/HER2- advanced breast cancer.
The trial uses the 400 mg BID fed regimen and has received FDA Breakthrough Therapy designation, underscoring the potential clinical impact of this approach.
Comparative Perspective: Evolution of PI3K Mutant Breast Cancer Treatment Options
The evolution of PI3K mutant breast cancer treatment options reflects a shift from broad, toxic inhibitors toward precision-targeted therapies.
Alpelisib established proof-of-concept but highlighted tolerability challenges. Inavolisib improved efficacy and safety, while capivasertib demonstrated the importance of pathway targeting beyond PI3K alone.
Zovegalisib represents the next step, combining mutant selectivity, allosteric inhibition, and improved tolerability, potentially redefining the treatment landscape.
Clinical Implications
The expanding range of PI3K mutant breast cancer treatment options provides clinicians with multiple strategies tailored to patient characteristics and prior therapies.
In current practice, treatment selection depends on prior exposure to CDK4/6 inhibitors, endocrine therapy, and patient comorbidities. The improved safety profiles of next-generation agents may enable earlier use and combination strategies, potentially improving long-term outcomes.
Conclusion
PI3K mutant breast cancer treatment options have evolved significantly, transitioning from first-generation inhibitors with substantial toxicity to highly selective, next-generation agents with improved efficacy and tolerability.
Zovegalisib represents a promising addition to this landscape, with encouraging early-phase data and ongoing Phase 3 evaluation. As clinical evidence continues to mature, these therapies have the potential to transform the management of PIK3CA-mutated breast cancer and address one of the most important resistance pathways in oncology.